Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
Journal of Clinical Oncology · 01.04.2024 · 42 (10) · 1135-1145
DOI: 10.1200/jco.23.00458 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.04.2024. Verfasst von Lucas Moreno und 47 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Topotecan, Neuroblastoma. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic agent bevacizumab (B). MATERIALS AND METHODS Patients age 1-21 years with RR-HRNB with adequate organ function and performance status were randomly assigned in a 3 × 2 factorial design to temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo) with or without B. The primary end point was best overall response (complete or partial) rate (ORR) during the first six courses, by RECIST or International Neuroblastoma Response Criteria for patients with measurable or evaluable disease, respectively. Safety, progression-free survival (PFS), and overall survival (OS) time were secondary end points. RESULTS One hundred sixty patients with RR-HRNB were included. For B random assignment (n = 160), the ORR was 26% (95% CI, 17 to 37) with B and 18% (95% CI, 10 to 28) without B (risk ratio [RR], 1.52 [95% CI, 0.83 to 2.77]; P = .17). Adjusted hazard ratio for PFS and OS were 0.89 (95% CI, 0.63 to 1.27) and 1.01 (95% CI, 0.70 to 1.45), respectively. For irinotecan ([I]; n = 121) and topotecan (n = 60) random assignments, RRs for ORR were 0.94 and 1.22, respectively. A potential interaction between I and B was identified. For patients in the bevacizumab-irinotecan-temozolomide (BIT) arm, the ORR was 23% (95% CI, 10 to 42), and the 1-year PFS estimate was 0.67 (95% CI, 0.47 to 0.80). CONCLUSION The addition of B met protocol-defined success criteria for ORR and appeared to improve PFS. Within this phase II trial, BIT showed signals of antitumor activity with acceptable tolerability. Future trials will confirm these results in the chemoimmunotherapy era.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vall d'Hebron University Hospital, Barcelona, Spain.
- University of Birmingham, Birmingham, United Kingdom.
- Children's Hospital Ireland, Dublin, Ireland.
- Institut Gustave Roussy, Paris, France.
- Hôpital des Enfants, Bordeaux, France.
- Hospital Universitario La Fe, Valencia, Spain.
ORCID-Profile: Lucas Moreno, Rebekah Weston, Marion Gambart, Victoria Castel, C Michel Zwaan, Karsten Nysom, Nicolas Gerber, Ruth Ladenstein, Guy Makin, Sucheta Vaidya, Natasha van Eijkelenburg, Deborah A Tweddle, Giuseppe Barone, Julie Tandonnet, Nadege Corradini, Pascal Chastagner, Catherine Paillard, Francisco J Bautista, Soledad Gallego Melcon, Bram De Wilde, Susan A Burchill, Gudrun Schleiermacher, Andrew Peet, Neil Jerome, Pamela Kearns, Andrew D J Pearson
Förderung
- Cancer Research UK
Zitieren
APA
Moreno, L., Weston, R., Owens, C., Valteau-Couanet, D., Gambart, M., Castel, V., Zwaan, C. M., Nysom, K., Gerber, N., Castellano, A., Laureys, G., Ladenstein, R., Rössler, J., Makin, G., Murphy, D., Morland, B., Vaidya, S., Thebaud, E., van Eijkelenburg, N., …, & Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN) (2024). Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. Journal of Clinical Oncology, 42(10), 1135-1145. https://doi.org/10.1200/jco.23.00458
Vancouver
Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, et al. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. Journal of Clinical Oncology. 2024;42(10):1135-1145. doi:10.1200/jco.23.00458
BibTeX
@article{Moreno2024,
author = {Moreno, Lucas and Weston, Rebekah and Owens, Cormac and Valteau-Couanet, Dominique and Gambart, Marion and Castel, Victoria and Zwaan, C Michel and Nysom, Karsten and Gerber, Nicolas and Castellano, Aurora and Laureys, Genevieve and Ladenstein, Ruth and Rössler, Jochen and Makin, Guy and Murphy, Dermot and Morland, Bruce and Vaidya, Sucheta and Thebaud, Estelle and van Eijkelenburg, Natasha and Tweddle, Deborah A and Barone, Giuseppe and Tandonnet, Julie and Corradini, Nadege and Chastagner, Pascal and Paillard, Catherine and Bautista, Francisco J and Gallego Melcon, Soledad and De Wilde, Bram and Marshall, Lynley and Gray, Juliet and Burchill, Susan A and Schleiermacher, Gudrun and Chesler, Louis and Peet, Andrew and Leach, Martin O and McHugh, Kieran and Hayes, Roisin and Jerome, Neil and Caron, Hubert and Laidler, Jennifer and Fenwick, Nicola and Holt, Grace and Moroz, Veronica and Kearns, Pamela and Gates, Simon and Pearson, Andrew D J and Wheatley, Keith and Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN), Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN)},
title = {Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {10},
pages = {1135--1145},
doi = {10.1200/jco.23.00458}
}
EUVIMED